2025 Pharmacy Forecast: High-Impact Drug Classes to Watch 

New biosimilars, expanded indications, and rising specialty utilization are poised to reshape the pharmacy landscape in 2025.  

In a new article for BenefitsPRO, Bradley Nelson, PharmD, Vice President of Clinical Services, and Tom Davies, PharmD, Vice President of Clinical Products, break down five drug classes that plan sponsors must watch – highlighting key shifts in anti-inflammatory and dermatology spend, as well as the growing influence of GLP-1 therapies beyond weight loss. 

As the market evolves, understanding which drug classes are driving spend – and why – is essential for proactive pharmacy benefits management.  

Read the full article on BenefitsPRO now.